Insider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Buys $27,300.00 in Stock

Key Points

• Insider buying: Anixa Biosciences director Lewis Titterton Jr. purchased 10,000 shares at $2.73 each, investing $27,300 and increasing his direct ownership to 996,967 shares.
• Stock and earnings: ANIX rose 1.8% to $2.81, while the company reported quarterly EPS of negative $0.08, in line with analyst expectations. Analysts expect a full-year loss of $0.31 per share.
• Analyst outlook: The stock carries a consensus “Hold” rating and a $10.00 price target, although ratings are mixed and institutional investors own 29.13% of the company.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis Titterton, Jr. bought 10,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was bought at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the purchase, the director directly owned 996,967 shares of the company's stock, valued at approximately $2,721,719.91. The trade was a 1.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Anixa Biosciences Trading Up 1.8%

Anixa Biosciences stock traded up $0.05 during mid-day trading on Monday, hitting $2.81. The company had a trading volume of 74,892 shares, compared to its average volume of 194,359. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46. The company's fifty day moving average is $3.33 and its 200-day moving average is $2.98. The company has a market capitalization of $97.68 million, a price-to-earnings ratio of -8.78 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). As a group, sell-side analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences during the 2nd quarter worth $33,000. Sanctuary Advisors LLC purchased a new stake in shares of Anixa Biosciences in the second quarter valued at about $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences during the second quarter worth about $29,000. Integrated Wealth Concepts LLC acquired a new position in Anixa Biosciences in the 2nd quarter valued at about $30,000. Finally, Cetera Investment Advisers acquired a new position in Anixa Biosciences in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 29.13% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Weiss Ratings cut Anixa Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, September 3rd. Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 20th. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. HC Wainwright reissued a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, Zacks Research lowered Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $10.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.